Related Experiment Video
Updated: Jul 7, 2026
03:43
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications
Nadine Jagerovic1, Cristina Fernandez-Fernandez, Pilar Goya
1Instituto de Química Médica, calle Juan de la Cierva, 3, E-28006 Madrid, Spain. nadine@iqm.csic.es
Current Topics in Medicinal Chemistry
|February 22, 2008
Summary
Researchers explored CB1 receptor antagonists, like rimonabant, for therapeutic uses. Structure-activity relationships of these cannabinoid CB1 receptor antagonists are reviewed for obesity and other applications.
Area of Science:
- Pharmacology
- Medicinal Chemistry
Background:
- Growing interest in modulating the cannabinoid CB1 receptor.
- Identification of CB1 receptor antagonists as a major advance in cannabinoid research.
- Development of rimonabant and related 1,5-diarylpyrazole structures.
Purpose of the Study:
- To review structure-activity relationships of CB1 receptor antagonists/inverse agonists.
- To discuss therapeutic applications of CB1 receptor antagonists.
- To highlight the potential of CB1 antagonists in treating obesity.
Main Methods:
- Review of existing literature on CB1 receptor antagonists.
- Analysis of structure-activity relationships based on rimonabant analogs.
- Examination of pharmacological and clinical study results.
Main Results:
- Numerous structural variations of 1,5-diarylpyrazoles have been developed.
- Rimonabant's clinical trials confirm therapeutic potential for obesity.
- Other pharmacotherapeutic applications have been identified.
Conclusions:
- CB1 receptor antagonists offer significant therapeutic potential.
- Understanding structure-activity relationships is key to developing novel CB1 antagonists.
- CB1 antagonists are promising for obesity and other medical conditions.
More Related Videos
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:28Drug-Receptor Interaction: Antagonist
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...